SCHEMBL140845

SCHEMBL140845

CCCCCCCCCCCCCCCCOS(C)(=O)=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.75
KDM4E B2RXH2 1/20 0.75
USP2 O75604 1/20 0.75
ALDH1A1 P00352 1/20 0.75
LMNA P02545 1/20 0.75
MMP9 P14780 1/20 0.75
ALOX15 P16050 1/20 0.75
CA1 P00915 15/20 0.64
CA2 P00918 15/20 0.64
CA9 Q16790 13/20 0.64
CA12 O43570 4/20 0.64
CA7 P43166 4/20 0.64
CA14 Q9ULX7 4/20 0.64
CA3 P07451 3/20 0.64
CA4 P22748 3/20 0.64
CA6 P23280 3/20 0.64
CA5A P35218 3/20 0.64
CA5B Q9Y2D0 3/20 0.64
RECQL P46063 2/20 0.61
GLA P06280 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11748392 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL5605250 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
Methanesulfonic Acid Dodecyl Ester SCHEMBL2223590 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL7726676 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL1899016 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL11225069 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL1443722 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL908020 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL3092383 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL11236129 1.00 TSHR (0.75) TSHRKDM4EUSP2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118652295-A Preparation method of 2' -hexadecyloxy guanosine derivative 安徽美华高科制药有限公司 2024-09-17 CN claimed
CN-115052854-A Salt of tranexamic acid ester 阿克特拉配料公司 2022-09-13 CN claimed
CN-103209985-B Phosphonate derivatives and methods of synthesis thereof 奇默里克斯公司 2016-08-24 CN claimed
US-20140046085-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof CHIMERIX, INC. (US) 2014-02-13 US claimed
CN-103209985-A Phosphonate derivatives and methods of synthesis thereof CHIMERIX INC 2013-07-17 CN claimed
EP-2611818-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF Chimerix, Inc. (US) 2013-07-10 EP claimed
WO-2012031045-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX, INC. (US) 2012-03-08 WO claimed
CN-1978431-A Ionic liquid using quaternary ammonium caprolactam as cation and its preparing method LANZHOU CHEM PHYS INST (CN) 2007-06-13 CN claimed
CN-118652295-A Preparation method of 2' -hexadecyloxy guanosine derivative 安徽美华高科制药有限公司 2024-09-17 CN disclosed
US-11603380-B2 Antiviral acyclonucleoside analogues for use in treating a viral infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-03-14 US disclosed
US-20210079031-A1 NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES NEOVIRTECH (FR) 2021-03-18 US disclosed
EP-3784680-A1 NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES Centre national de la recherche scientifique (FR) 2021-03-03 EP disclosed
US-20190322958-A1 Lubricant Composition BASF SE (DE) 2019-10-24 US disclosed
US-20190322958-A1 Lubricant Composition BASF SE (DE) 2019-10-24 US disclosed
US-5138067-A PAF antagonists, antithrombotic, antivasoconstricting, antibronchoconstricting or antitumor agents SHIONOGI & CO. LTD. (JP) 1992-08-11 US disclosed
US-5087721-A Tumor-specific; for diagnosis and therapy THE UNIVERSITY OF MICHIGAN (US) 1992-02-11 US disclosed
US-5047540-A Platelet Activating Factor Antagonists and Antitumor Agents SHIONOGI & CO., LTD. (JP) 1991-09-10 US disclosed
US-4965391-A Tumor specific THE UNIVERSITY OF MICHIGAN (US) 1990-10-23 US disclosed
EP-0321296-A1 Lipid derivatives their preparation and use SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1989-06-21 EP disclosed
EP-0072531-A1 Derivatives of cyclophosphamide, process for their preparation and their use Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1983-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603380-B2 Antiviral acyclonucleoside analogues for use in treating a viral infection TYMP, EIF2AK2, ENTPD5 TSHR 4665/4885KDM4E 3270/4885USP2 3819/4885
US-20210079031-A1 NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES TYMP, EIF2AK2, PNP TSHR 4758/4885KDM4E 3588/4885USP2 3968/4885
US-20140046085-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof PHOSPHO1, PIK3CA, PNP TSHR 3965/4885KDM4E 1612/4885USP2 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.